Gilead Sciences (GILD)

63.15 -0.79 (1.24%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/4/20)
- M&A (12/31/17 *Est)

Latest Headlines

Gilead Sciences (GILD) is assessing its Ebola drug as possible coronavirus treatment - Bloomberg January 23, 2020 1:33 PM - StreetInsider S&P 500 gains, Nasdaq hits new high as investors eye earnings, coronavirus January 23, 2020 8:20 AM - StreetInsider Gilead Sciences to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 4, 2020 January 21, 2020 5:30 PM - BizWire Guggenheim Downgrades Gilead Sciences (GILD) to Neutral January 21, 2020 9:05 AM - StreetInsider Gilead Sciences (GILD) Strategic Update May Disappoint But Stock Remains Undervalued, RBC Capital Reiterates Top Pick Rating January 14, 2020 6:52 AM - StreetInsider Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences January 13, 2020 5:45 AM - PR NewsWire Gilead Sciences (GILD) Licenses Portfolio of HIV Antibodies From The Rockefeller University January 9, 2020 8:31 AM - StreetInsider Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University January 9, 2020 8:30 AM - BizWire Scholar Rock Holding Corp. (SRRK) Reports $25M Milestone Payment from Strategic Fibrosis Collaboration with Gilead Sciences (GILD) January 9, 2020 7:37 AM - StreetInsider Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences January 9, 2020 7:31 AM - StreetInsider Xencor (XNCR), Gilead (GILD) Enter License Agreement for Use of XmAb Antibody Technologies in Investigational Agents for HIV January 8, 2020 8:07 AM - StreetInsider Form 4 GILEAD SCIENCES INC For: Jan 03 Filed by: Pletcher Brett A January 6, 2020 7:01 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Dec 30 Filed by: Whitley Richard James January 2, 2020 4:30 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Dec 30 Filed by: Lofton Kevin E January 2, 2020 4:19 PM - SEC Filing More drugmakers hike U.S. prices as new year begins January 1, 2020 11:20 AM - StreetInsider William Blair Sees Biotech M&A Continuing in 2020; Issues Top 10 Predictions December 31, 2019 7:03 AM - StreetInsider Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval December 24, 2019 1:00 AM - BizWire Gilead Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 December 23, 2019 8:01 AM - BizWire Gilead Sciences (GILD) Announces China NMPA Approves Vosevi for People With Chronic Hepatitis C Infection Who Require Re-Treatment December 20, 2019 8:31 AM - StreetInsider China National Medical Products Administration Approves Vosevi® (Sofosbuvir, Velpatasvir and Voxilaprevir) for People With Chronic Hepatitis C Infection Who Require Re-Treatment December 20, 2019 8:30 AM - BizWire Gilead Sciences (GILD) Submits Filgotinib NDA to FDA Under Priority Review for Rheumatoid Arthritis Treatment December 19, 2019 4:30 PM - StreetInsider Gilead Submits Filgotinib New Drug Application to U.S. Food and Drug Administration Under Priority Review for Rheumatoid Arthritis Treatment December 19, 2019 4:30 PM - BizWire Gilead submits new drug application to U.S. Food and Drug Administration under priority review for filgotinib for rheumatoid arthritis treatment December 19, 2019 4:30 PM - StreetInsider Where's the risk? U.S. fund managers bet on bull run in 2020 December 18, 2019 7:09 AM - StreetInsider Gilead Sciences (GILD) Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis and Compensated Cirrhosis Due to NASH December 16, 2019 8:03 AM - StreetInsider  Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) December 16, 2019 8:00 AM - BizWire Bristol-Myers Squibb (BMY) Wins Patent Royalty Fight Against Gilead Sciences (GILD), Awarded $585M in Damages, Plus Royalty - Bloomberg December 13, 2019 2:29 PM - StreetInsider Gilead (GILD) Set to Open Lower Following Downgrade December 13, 2019 6:30 AM - StreetInsider UPDATE: Credit Suisse Downgrades Gilead Sciences (GILD) to Underperform December 13, 2019 4:55 AM - StreetInsider Activists say a patent office lawyer’s tweets showed ‘bias’ in favor of Gilead (GILD) in HIV drug case - STAT's Feuerstein December 12, 2019 1:20 PM - StreetInsider Popular stocks with increasing unusual: GILD LULU M HD FCX December 12, 2019 4:48 AM - StreetInsider Gilead Sciences' (GILD) Kite Submits BLA to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy December 11, 2019 4:09 PM - StreetInsider Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy December 11, 2019 4:05 PM - BizWire Exelixis (EXEL) Gains on Chatter December 11, 2019 10:52 AM - StreetInsider Kite (GILD), Kiniksa (KNSA) Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta and Mavrilimumab in R/R Large B-Cell Lymphoma December 11, 2019 8:31 AM - StreetInsider Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma December 11, 2019 8:31 AM - StreetInsider Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma December 11, 2019 8:30 AM - Globe NewsWire Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma December 11, 2019 8:30 AM - BizWire Gilead Sciences' (GILD) Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma December 9, 2019 2:46 PM - StreetInsider Gilead Sciences' (GILD) Kite and CIBMTR Present Positive Findings From Real-World Use of Yescarta in Relapsed or Refractory Large B-Cell Lymphoma December 9, 2019 2:46 PM - StreetInsider Kite and the CIBMTR® Present Positive Findings From Real-World Use of Yescarta® (Axicabtagene Ciloleucel) in Relapsed or Refractory Large B-Cell Lymphoma December 9, 2019 2:45 PM - BizWire Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma December 9, 2019 2:45 PM - BizWire Sanders, Ocasio-Cortez Seeks Patent Extension Denial for Gilead (GILD), Urges Govt. to Allow HIV Drugs to be Made Generically - Bloomberg December 9, 2019 10:49 AM - StreetInsider Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment December 7, 2019 2:00 PM - BizWire Form 4 GILEAD SCIENCES INC For: Dec 03 Filed by: Pletcher Brett A December 4, 2019 7:11 PM - SEC Filing National AIDS Memorial Receives $2.4 Million Donation From Gilead Sciences to Support the AIDS Memorial Quilt as It Moves Home to San Francisco November 27, 2019 2:16 PM - BizWire Form 4 GILEAD SCIENCES INC For: Nov 25 Filed by: Pletcher Brett A November 26, 2019 2:15 PM - SEC Filing Exclusive: Sanofi's strategy boss to leave as CEO readies revamp November 22, 2019 6:42 AM - StreetInsider Industry Veterans Appointed to Head the Global Technical Operations and Clinical Development Organizations at Kite November 21, 2019 8:30 AM - BizWire Form 4 GILEAD SCIENCES INC For: Nov 14 Filed by: Pletcher Brett A November 20, 2019 6:11 PM - SEC Filing Amarin (AMRN) Smacked on Bearish Call, But Gilead (GILD) Adding Vascepa to its NASH Combo Raises Eyebrows November 20, 2019 11:11 AM - StreetInsider Gilead Sciences (GILD) 'Quietly' Added Amarin's (AMRN) Vascepa to an Old NASH Combo Trial - Raymond James November 19, 2019 5:38 PM - StreetInsider Form 4 GILEAD SCIENCES INC For: Nov 10 Filed by: Dickinson Andrew D November 12, 2019 6:49 PM - SEC Filing Form 4 GILEAD SCIENCES INC For: Nov 10 Filed by: Parsey Merdad November 12, 2019 6:35 PM - SEC Filing UPDATE: SunTrust Starts Gilead Sciences (GILD) at Hold November 12, 2019 4:32 AM - StreetInsider New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile November 9, 2019 4:30 PM - BizWire NEW DATA ON FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) DEMONSTRATE DURABLE EFFICACY AND SAFETY PROFILE November 9, 2019 4:30 PM - StreetInsider Telecom 'staples,' healthcare stocks set to shine, says Ariel's Bhansali November 8, 2019 12:11 PM - StreetInsider Gilead Presents Data on Investigational HIV-1 Capsid Inhibitor GS-6207 as a Potential Component of Long-Acting HIV Therapy November 8, 2019 8:00 AM - BizWire Gilead Announces New Data from Viral Hepatitis Research Programs at The Liver Meeting® 2019 November 8, 2019 8:00 AM - BizWire Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019 November 8, 2019 8:00 AM - BizWire Form 4 GILEAD SCIENCES INC For: Nov 05 Filed by: Pletcher Brett A November 7, 2019 8:05 PM - SEC Filing HHS Lawsuit a 'Non-Event' for Gilead Sciences (GILD) - RBC November 7, 2019 1:50 PM - StreetInsider Gilead Sciences (GILD) option implied volatility flat into American Society of Hematology (ASH) Annual Meeting November 7, 2019 5:15 AM - StreetInsider Form 3 GILEAD SCIENCES INC For: Nov 01 Filed by: Parsey Merdad November 6, 2019 4:32 PM - SEC Filing Form 3 GILEAD SCIENCES INC For: Nov 01 Filed by: Dickinson Andrew D November 6, 2019 4:29 PM - SEC Filing Galapagos increases share capital through warrant exercise by Gilead November 6, 2019 4:01 PM - StreetInsider Gilead Sciences' (GILD) Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH November 6, 2019 9:03 AM - StreetInsider Kite to Present New Data From Industry-leading Cell Therapy Portfolio at ASH 2019 November 6, 2019 9:00 AM - BizWire Gilead Sciences (GILD) Reports Biktarvy Maintained High Efficacy w/no Cases of Treatment-Emergent Resistance Through 3-Yrs in Ph. 3 HIV Clinical Trials November 6, 2019 6:56 AM - StreetInsider Gilead Presents 96-week Discover Trial Data Supporting Non-inferior Efficacy and Key Safety Differences of Descovy For PrEP™ Compared With Truvada For PrEP® November 6, 2019 6:45 AM - BizWire Gilead’s Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials November 6, 2019 6:45 AM - BizWire Form 4 GILEAD SCIENCES INC For: Nov 01 Filed by: Pletcher Brett A November 5, 2019 8:22 PM - SEC Filing Form 10-Q GILEAD SCIENCES INC For: Sep 30 November 5, 2019 5:17 PM - SEC Filing BeiGene, Ltd. (BGNE) PT Raised to $210 at Maxim Group November 4, 2019 7:53 AM - StreetInsider Gilead (GILD) delivers exercise notice to Galapagos (GLPG) for Initial Warrant A to increase ownership to 25.1% November 1, 2019 4:02 PM - StreetInsider Gilead delivers exercise notice to Galapagos for Initial Warrant A to increase ownership to 25.1% November 1, 2019 4:01 PM - StreetInsider Gilead Sciences (GILD), Galapagos (GLPG) to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting October 31, 2019 4:46 PM - StreetInsider Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting October 31, 2019 4:01 PM - BizWire GILEAD AND GALAPAGOS TO PRESENT NEW DATA ON FILGOTINIB AT 2019 ACR/ARP ANNUAL MEETING October 31, 2019 4:01 PM - StreetInsider Form 4 GILEAD SCIENCES INC For: Oct 28 Filed by: Pletcher Brett A October 30, 2019 8:35 PM - SEC Filing Merck (MRK) losses bid to revive $2.5B verdict against Gilead Sciences (GILD) - Bloomberg October 30, 2019 9:29 AM - StreetInsider RBC Capital Positive on Gilead Sciences (GILD) on 'Intriguing' Capsid Ph.II Trial Design October 29, 2019 1:41 PM - StreetInsider Gilead Sciences (GILD), Glympse Bio Report Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development October 28, 2019 8:05 AM - StreetInsider Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development October 28, 2019 8:00 AM - BizWire Gilead Sciences (GILD) PT Raised to $90 at RBC Capital October 28, 2019 6:36 AM - StreetInsider Full Article List